HWM
PRLD icon

HighMark Wealth Management’s Prelude Therapeutics PRLD Stock Holding History

HighMark Wealth Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50
Closed -$64 – 597
2024
Q4 		$64 Hold
50
– – ﹤0.01% 566
2024
Q3 		$104 Hold
50
– – ﹤0.01% 580
2024
Q2 		$191 Hold
50
– – ﹤0.01% 564
2024
Q1 		$237 Hold
50
– – ﹤0.01% 550
2023
Q4 		$214 Hold
50
– – ﹤0.01% 555
2023
Q3 		$155 Hold
50
– – ﹤0.01% 549
2023
Q2 		$225 Hold
50
– – ﹤0.01% 539
2023
Q1 		$285 Hold
50
– – ﹤0.01% 575
2022
Q4 		$302 Hold
50
– – ﹤0.01% 510
2022
Q3 		$0 Hold
50
– – ﹤0.01% 549
2022
Q2 		$0 Hold
50
– – ﹤0.01% 532
2022
Q1 		$0 Hold
50
– – ﹤0.01% 531
2021
Q4 		$1K Buy
+50
New +$813 ﹤0.01% 478

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighMark Wealth Management's PRLD Position: Q1 2025 in Review

HighMark Wealth Management sold out of Prelude Therapeutics (PRLD) in Q1 2025, closing a stake of 50 shares — an estimated $64 sold.

HighMark Wealth Management first reported a position in PRLD in Q4 2021 and held it in 13 quarters. The position peaked at $1K in Q4 2021. 59 funds tracked by Wall St. Rank hold PRLD as of Q1 2025.

  • HighMark Wealth Management reported no remaining Prelude Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HighMark Wealth Management sold 50 Prelude Therapeutics shares in Q1 2025, an estimated $64.
  • HighMark Wealth Management first reported a position in Prelude Therapeutics in Q4 2021 and held it in 13 quarters.
  • HighMark Wealth Management's Prelude Therapeutics position peaked at $1K in Q4 2021.
  • 59 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2025.

Based on HighMark Wealth Management's 13F filing for Q1 2025, filed 24 Apr 2025.